Clinical Research Directory
Browse clinical research sites, groups, and studies.
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
Sponsor: M.D. Anderson Cancer Center
Summary
This phase II trial studies the effect of baloxavir in combination with oseltamivir in treating severe influenza infection in patients who have previously received a hematopoietic (blood) stem cell transplant or have a hematological malignancy. Baloxavir is an antiviral drug that inhibits the growth of influenza virus, reduces viral load and prevents further influenza infection. Osetamivir is an antiviral drug that blocks enzymes on the surfaces of influenza viruses, interfering with cell release of complete viral particles. Giving baloxavir in combination with oseltamivir may shorten or decrease the intensity of influenza infection compared to oseltamivir alone.
Official title: Efficacy of Combination Baloxovir and Oseltamivir Therapy in Influenza Infected Immunocompromised Hosts
Key Details
Gender
All
Age Range
12 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2021-10-11
Completion Date
2028-02-28
Last Updated
2026-02-11
Healthy Volunteers
No
Interventions
Baloxavir Marboxil
Given PO
Oseltamivir
Given PO
Locations (1)
M D Anderson Cancer Center
Houston, Texas, United States